ADIPOQ and metabolic dysfunction-associated steatotic liver disease: Rahmanabadi et al. [40] report that oral ALA supplementation (1200 mg/12 weeks) resulted in a significant reduction in the serum leptin concentration and a noticeable elevation in the adiponectin-to-leptin ratio in patients with non-alcoholic fatty liver disease.